Introduction
The Notch pathway is an evolutionarily conserved signaling pathway that plays a critical role in many developmental decisions including proliferation, differentiation and apoptosis. 1, 2 In mammals, four different transmembrane Notch receptors (Notch-1, -2, -3 and -4) have been described, which interact with members of the Delta and Jagged families of Notch ligands including Delta-1, Delta-4, Jagged-1 and Jagged-2. 3, 4 In mammalian development, the critical role of Notch signaling has been illustrated by the severe defects and embryonic lethality observed in knockout mice. Homozygous mutant mice lacking functional Notch-1 or Notch-2 genes develop normally until days 9 and 11.5, respectively and then die in utero. [5] [6] [7] Similarly, mutations in Delta-1 or Jagged-1 are embryonically lethal 8 while Jagged-2 null mice die perinatally displaying severe limb, craniofacial and thymic developmental defects. 9 The primary effect of Notch activation appears to be suppression of differentiation and lineage commitment allowing responding cells to remain in more primitive state. 2, 10 In human hematopoiesis, a role for Notch was first indicated following the identification of human Notch-1 (hNotch-1) (TAN-1) that was cloned from human leukemic T-cells, whose transformation involved a translocation between the hNotch-1 and T-cell receptor b genes. 11, 12 Since the initial reports, several studies in the mouse and human have shown that Notch plays a role in the development of the mammalian hematopoietic system by inhibiting the differentiation of myeloid and granulocytic cell lines and maintaining primitive progenitors. [13] [14] [15] [16] While most evidence to date suggests that Notch may play a role in the maintenance of primitive and highly proliferative hematopoietic cell populations, other reports suggest that Notch activation may promote the differentiation of progenitors. 17, 18 The reasons for these contrasting results are not clear, but could be because of differences in specific Notch ligand/receptor interactions and other regulatory/modulatory factors occurring at different stages of hematopoiesis. 17 Using a purified population of CD34+CD38ÀLinÀ cells from umbilical cord blood (CB), the Notch ligands Jagged-1 and Delta-1 have been shown to maintain and expand primitive CD34+ cells capable of repopulating the BM of NOD/SCID mice. 13, 19 Although cell surface expression of the CD34 antigen has been considered as the most indicative marker of human repopulating cells, recent studies indicate that cells devoid of the CD34 marker (CD34À cells) are also capable of repopulation. [20] [21] [22] [23] [24] [25] Initial observations that CD34À cells were capable of long-term reconstitution in mice were reported by Osawa et al, 26 who showed that a single CD34À, Sca-1+ c-kit+ cell transplanted into lethally irradiated mice resulted in multilineage hematopoietic reconstitution. In humans, CD34Àscid repopulating cells (CD34 neg -SRC) capable of multilineage reconstitution were identified, suggesting that existence of CD34 À hematopoietic stem cells is not species specific. 22 Based on both their progenitor capacity and repopulation characteristics, primitive CD34À cells appear to be functionally distinct from CD34+ cells. 22, 27 In addition, CD34À cells appear to be more primitive and are capable of giving rise to CD34+ cells both in vitro and in vivo. 23, 28 A small proportion (about 0.2%) of CD34À cells derived from lineage-depleted (LinÀ) CB cells also express a 120 kDa surface glycoprotein, called AC133. 25 Expression of AC133 on the subset of CD34ÀLinÀ cells appears to be an important marker for the enrichment of progenitor/stem cell function, since only the AC133+ cells (AC133+CD34À) show SRC capacity, while the AC133À cells (AC133ÀCD34À) do not have this function nor can they give rise to CD34+ cells in culture. 25 Here, we have compared the expression patterns of Notch signaling genes in primitive human CD34À and CD34+ hematopoietic cell subsets. While most Notch genes examined were expressed in all cell subsets studied, Notch-3 and Notch-4 could not be detected in AC133+CD34ÀLinÀ cells. Purified cell subpopulations were treated with Jagged-1 and analyzed for cellular proliferation, phenotypic differentiation and clonogenic progenitor capacity. Unlike in the CD34+ cell subset, Jagged-1 treatment did not enhance the proliferation of CD34À cells, or differentiation of CD34À cells into CD34+ cell phenotype. The lack of Jagged-1-induced activation in CD34À cells did not appear to be related to the expression of Fringe, which was expressed in all parent and progeny populations investigated. Surprisingly, CD34+ progeny of differentiated CD34À cells did not express Notch-3 or Notch-4 upon differentiation, unlike CD34+ from CD34+CD38À cells. Our results further illustrate the functional distinctiveness of the primitive CD34À subsets from the CD34+ cells, by indicating that primitive CD34À cells respond differentially to Jagged-1. We suggest that this distinct response may be because of the absence of Notch-3 or Notch-4 expression in de novo isolated CD34À cells and their CD34+ daughters.
Materials and methods

Cell purification
Human umbilical CB mononuclear cells were isolated and enriched for lineage-depleted cells (LinÀ) as previously described. 25 Briefly, mononuclear cells were incubated with a cocktail of lineage antibodies and enriched for LinÀ by negative selection using an immunomagnetic column and protocols similar to that described by the manufacturers (StemSep TM ; Stem Cell Technologies Inc., Vancouver, BC, Canada). LinÀ cells were stained with anti-human CD34 fluorescein isothiocyanate (FITC), anti-human CD38 allophycocyanin (APC) (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA) and antihuman AC133 phycoerythrin (PE) (Miltenyi Biotec, Auburn, CA, USA). Enriched cell populations comprising of AC133+ CD34ÀCD38ÀLinÀ(AC133+CD34À), AC133ÀCD34ÀCD38ÀLin À(AC133ÀCD34À) and CD34+CD38ÀLinÀ(CD34+CD38À) were sorted on a fluorescence-activated cell sorter (FACS, Vantage SE, Becton Dickinson) as previously described. 25 Appropriate antibody isotype-matched controls were used to define background staining and to establish the sorting gates as shown in Figure 1 . Data acquisition and analysis were performed using Cell Quest software (Becton Dickinson, Immunocytometry Systems (BDIS), San Jose, CA, USA).
RT-PCR analysis of Notch pathway gene expression in human CD34À and CD34+ cells Purified cells isolated from full-term umbilical CB were used for the isolation of mRNA according to the kit manufacturer's instructions (QuickPrep R Micro RNA purification Kit, Amersham Pharmacia Biotech, Buckinghamshire, England). The mRNA was reverse transcribed into first-strand cDNA according to kit manufacturer's instructions (First Strand cDNA Synthesis Kit, Amersham Pharmacia Biotech, Buckinghamshire, England). PCR amplification reactions were performed using a PerkinElmer 9700 thermal cycler (Foster City, CA, USA) using previously optimized conditions. 13, 19 The following primer sequences were used: Notch-1 forward 5
Figure 1
Establishment of sorting gates for the isolation of AC133+CD34ÀCD38ÀLinÀ, AC133ÀCD34ÀCD38ÀLinÀ and CD34+CD38ÀLinÀ cell subsets. LinÀ cells prepared as detailed in the Materials and methods were stained with anti-human CD34 FITC, CD38 APC and AC133 PE antibodies (Becton Dickinson, Immunocytometry Systems (BDIS), San Jose, CA, USA and Miltenyi Biotec, Auburn, CA, USA). The appropriate isotype-matched controls were used to show background staining and establish sorting gates. The forward and side scatter properties were used to gate live cells (R1) (i) which were sorted using histogram region profiles as follows: R2, R5 and R6 were used for AC133+CD34ÀCD38Àcells and R2, R4 and R6 were for AC133ÀCD34ÀCD38À cells (ii-iv), while R3 and R6 were used for the CD34+CD38À cells (ii and iv). Reanalysis of sorted cells indicated purity of 497% for the various populations (data not shown). 0 -GCTCTGAATAATGGGCTTCTG-3 0 . The PCR products were sequenced to verify specificity of amplified cDNA sequences.
Preparation of soluble hJagged-1 chimeric protein
The preparation of hJagged-1 protein was previously described. 13 Briefly, human Jagged-1 cDNA was isolated by plaque hybridization from human placenta and fetal brain cDNA libraries (Clontech, Palo Alto, CA, USA). Partial cDNA encoding the entire extracellular domain of Jagged-1 was fused in frame to a sequence of human IgG1 and inserted into the expression vector pcDNA3 (Invitrogen, San Diego, CA, USA) or pMKITneo (kindly provided by Dr K Maruyama, Tokyo Medical and Dental University). The expression vectors were introduced into CHO cells by electroporation and the cells were subsequently selected in the presence of G418. Expression of soluble Jagged-1 protein was verified on Western blots with antihuman IgG1 antibody (Amersham, UK). The human IgG1 chimeric proteins were purified from conditioned media by affinity chromatography according to methods previously described.
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Liquid serum-free cultures of purified cells Purified cell populations of AC133+CD34À, AC133ÀCD34À and CD34+CD38À cells were cultured in serum-free media containing hematopoietic cytokines as previously described. 25 Briefly, serum-free cultures contained 9500 BIT media (Stem Cell Technologies Inc., Vancouver, Canada) supplemented with 10 À4 M b-mercaptoethanol and 2 mM L-glutamine (Gibco BRL). The growth factor cocktail was used at final concentrations of 300 ng/ml of recombinant human Flt-3 (rhu-Flt-3) and rhu-SCF, 50 ng/ml rhu-G-CSF (R&D Systems, Minneapolis, MN, USA), and 10 ng/ml of rhu-IL-3 and rhu-IL-6 (Amgen Inc., Thousand Oaks, CA, USA). Cells were cultured for 10 days at 371C and 5% CO 2 either in hematopoietic cytokines alone or in the presence of 10 mg/ml hJagged-1-IgG1 added every other day. Initial experiments with recombinant IgG1 protein added to control for nonspecific effects of IgG1 in the hJagged-1 chimeric protein showed no effects of IgG protein on cells in culture. Harvested cells were counted and stained with anti-human CD34 APC or anti-human AC133 PE for phenotypic analysis by flow cytometry (FACS Calibur, Becton Dickinson, San Jose, CA, USA).
Clonogenic progenitor and long-term culture initiating cell assays
Human clonogenic progenitor assays were performed by plating an equivalent number of hJagged-1 or untreated control cells using previously defined culture conditions. 13 Briefly, cells were plated in methylcellulose cocktail (Methocult H4432, Stem Cell Technologies), containing 50 ng/ml recombinant human (rhu) SCF, 10 ng/ml rhu IL-3, 10 ng/ml GM-CSF, and 3 U/ml rhu erythropoietin. The cells were incubated at 371C and 5% CO 2 in a humidified atmosphere. Colonies were counted and scored by morphological characteristics after 10-14 days in culture using an inverted microscope. The long-term culture initiating cell (LTC-IC) assays were essentially performed as previously described. 30 De novo isolated or cultured cells were placed on primary mouse bone marrow stroma in replicate wells at different cell concentrations for 5 weeks with regular media changes, followed by plating in methylcellulose medium for 10-14 days. The wells were scored for the presence (positive) or absence (negative) of colonies. 31, 32 Results
Phenotypic isolation of human CB CD34À and CD34+ cell subsets
To determine the expression of Notch pathway genes and examine the role of Notch regulation, human CD34ÀLinÀ and CD34+LinÀ cells were purified from full-term CB using the gating strategy indicated in Figure 1 . Since multilineage repopulating function of human CD34+ cells in NOD/SCID mice has been associated with the fraction that does not express the CD38 antigen, subfractions isolated were devoid of CD38 expression. 33 Human CD34À cells were further purified on the basis of AC133 expression into AC133+CD34ÀCD38ÀLinÀ (AC133+CD34À) and AC133ÀCD34ÀCD38ÀLinÀ(AC133 ÀCD34À) subsets. 25 The sorting gates were established by using the appropriate murine IgG 1 isotype-matched control antibodies to establish background levels of staining as shown. Live cells (gated R1) ( Figure 1i ) were isolated based on the histogram profiles shown as follows: regions R2, R5 and R6 were used to isolate the AC133+CD34ÀCD38ÀLinÀ cells, while R2, R4 and R6 were used to isolate AC133ÀCD34ÀCD38ÀLinÀ cells (Figure 1ii-iv) . The CD34+CD38ÀLinÀcells were isolated by using the histogram profile regions R3 and R6 (Figure 1ii and iv). Highly purified (497% purity) subfractions of AC133+CD34ÀCD38ÀLinÀ, AC133ÀCD34ÀCD38ÀLinÀand CD34+CD38ÀLinÀ were used for subsequent analysis.
Comparative expression of Notch-1, -2, -3 and -4 between human CD34
À and CD34 + subsets
To comparatively examine the expression profile of Notch receptors in primitive human hematopoietic cells, cDNA from purified LinÀ CB AC133+CD34À, AC133ÀCD34À and CD34+CD38À cells was analyzed by RT-PCR. Both CD34À derived subpopulations (AC133+CD34À and AC133ÀCD34À) and CD34+CD38ÀLinÀ cells expressed the receptors Notch-1 and Notch-2 (Figure 2ai and ii) . Surprisingly, however, the CD34À cell subsets showed differential expression of the Notch-3 and Notch-4 receptors. AC133ÀCD34À cells expressed both Notch-3 and Notch-4, similar to CD34+CD38ÀLinÀ cells, while AC133+CD34À cells did not detectably express either of these two genes (Figure 2ai and ii). All cell subsets examined expressed the Notch ligand Jagged-1 as well as the Notch processing metalloprotease, Kuzbanian (Figure 2ai and ii). The Kuzbanian gene, which belongs to the a-disintegrin and metalloproteinase superfamily of metallopro-teinases, is one of several protease genes that play critical roles in both Notch receptor and ligand maturation, regulation and function. [34] [35] [36] [37] These data suggest that AC133+CD34À cells have distinct Notch receptor expression, which may relate to differential responsiveness to the Notch ligands.
Owing to the lack of Jagged-1-induced responses in CD34À cells when compared to CD34+ cells as detailed below, we examined whether Fringe, a negative modulator of Jagged-1-induced activation acting through Notch-1 or Notch-2 4,38 was expressed in de novo isolated CD34Àand CD34+cells. Fringe expression was detected in both CD34À(AC133+CD34ÀLinÀ) and CD34+(CD34+CD38ÀLinÀ) cells (Figure 2b ). Sequence analysis suggested Manic Fringe was the predominant transcript expressed in primitive human hematopoietic cells (data not shown). Based on these observations, Fringe may be equally important in modulating response of CD34À and CD34+ cells to putative Notch ligands.
Effects of Jagged-1 on proliferation of purified CD34À and CD34+ subsets
To determine the effects of Jagged-1 on primitive hematopoietic cell populations, purified AC133+CD34ÀLin and CD34+CD38ÀLinÀ cells were cultured in serum-free conditions containing growth factors previously shown to maintain Expression profile of components of the Notch pathway in human hematopoietic CD34À and CD34+ cells. LinÀ cells were sorted by flow cytometry into AC133+CD34ÀCD38À, AC133ÀCD34ÀCD38À or CD34+CD38À populations and reanalyzed to verify level of purification (497% purity). Purified cells were used to prepare cDNA for Notch RT-PCR analysis using primers designed from previously published sequences and from available databases. Fetal cDNA was used as the positive control, while bglucuronidase was used to assess the quality and integrity of cDNA templates generated. Proliferative and clonogenic progenitor analysis of human AC133+CD34ÀCD38ÀLinÀ and CD34+CD38ÀLinÀ cells cultured in serum-free conditions in the presence or absence of hJagged-1. Highly purified AC133+CD34ÀCD38ÀLinÀ and CD34+CD38ÀLinÀ cells were isolated (purity 497%) and seeded in 96-well plates containing serum-free medium and hematopoietic cytokines in the presence or absence of 10 mg/ml of soluble hJagged-1. Cells were harvested after 10 days and analyzed for fold expansion relative to number of cells seeded on day 0. (a) Fold increase in total cell number for control or hJagged-1-treated cells is shown for (i) AC133+CD34ÀCD38À and (ii) CD34+CD38À cells. Effect of hJagged-1 treatment on the number of clonogenic progenitors was analyzed in methylcellulose culture following 10 days of ex vivo culture in serum-free conditions. Between 3000 and 3500 cells were plated in methylcellulose medium and scored 10-14 days later for the frequency and types of colonies. 33 In human CB, the majority (490%) of CD34ÀLinÀ cells do not express the AC133 antigen (AC133ÀCD34À). Although these cells are present in larger numbers than the CD34ÀAC133+ cells, they consistently showed very poor growth and survival in 10 days serum-free culture conditions even when seeded at 20-30 times the cell number of AC133+CD34À cells. Therefore, the AC133À CD34À cells were not subjected to further analysis in these experiments, and will not be discussed further in this report.
Jagged-1 effects on primitive human CD34À and CD34+ cells
Cultured cells were harvested after 10 days and analyzed for cellular proliferation. Addition of Jagged-1 to cultures containing AC133+CD34Àcells had no effect on the overall proliferation of the cultured cells when compared to untreated controls (Figure 3ai) . In contrast, when CD34+ CD38À cells were cultured for similar periods of time, there was a significant increase in total cell number following treatment with Jagged-1 compared to controls (Figure 3aii) . Addition of recombinant IgG 1 protein at equivalent concentration to the Jagged-1 protein had no effect on cells when compared to conditions with hematopoietic cytokines alone (data not shown).
Hematopoietic progenitor function of cultured human CD34À and CD34+ hematopoietic cells
In addition to proliferative and phenotypic analysis, functional in vitro assays for myeloid clonogenic progenitors (CFU assay) were performed on cultured CD34À and CD34+ cells. (Figure 3bii) . A significantly higher number of total progenitors in Jagged-1-treated cells was observed with 14911.377479.7 colonies in Jagged-1-treated wells, compared to 41037850.6 colonies for the untreated controls, (Figure 3cii ). There were no significant differences in the composition and types of colonies between the control and Jagged-1-treated cells for either the AC133+CD34À or CD34+CD38À cells (Table 1) . Collectively, these data illustrate that unlike Jagged-1 treatment of human CD34+CD38À cells, treatment of AC133+CD34À cells in ex vivo culture does not positively enhance, and in fact appears to inhibit, the proliferation and maintenance of primitive clonogenic progenitors.
The LTC-IC assay provides a measure of proliferative and differentiative capacities of primitive human hematopoietic cells in vitro.
31,39 LTC-IC assays were carried out using de novo isolated CD34À and CD38+ cells and 10-day cultured cells. There was no detectable difference in the presence or absence of Jagged-1 on LTC-IC capacity detected from CD34À or CD34+ cells following 10 days of culture (data not shown).
In vitro differentiation potential of AC133+ CD34À and CD34+CD38Àcells
Cultured cells were examined for the comparative expression of the CD34 surface antigen in AC133+CD34À and CD34+CD38À cells following 10 days of treatment in the presence or absence of hJagged-1. For phenotypic analysis, live cells were gated based on forward and side scatter (R1) and 7AAD exclusion R2 (Figure 4ai and ii). For the AC133+CD34À cells, acquisition of CD34+ phenotype was fairly similar in controls (15.473.5%) when compared to hJagged-1-treated cells (12. 173.3%) (Figure 4aiii and iv) . In both control and hJagged-1-treated cells, the majority (497%) of the original AC133+ CD34À cells that remained CD34À after culture also lost the AC133 marker to become AC133À CD34À, while only about 50% of those cells that acquired CD34 lost the AC133 marker (AC133ÀCD34+) (Figure 4aiii and iv) . For the CD34+CD38À cell subset, the frequency of post-culture CD34+ cells following hJagged-1 treatment (21.074.9%) was similar to untreated controls (19.774.6 (Figure 4av and vi) . For both parental CD34À and CD34+, there appears to be a linear relation between CD34+ and AC133+ expression following culture, similar to that observed in de novo isolated cells. 25 Owing to higher overall cellular proliferation of the Jagged-1-treated CD34+CD38À cells compared to controls (Figure 3aii ), the absolute cell number of CD34+ cells in hJagged-1-treated Table 1 Composition of clonogenic progenitors present in AC133+CD34ÀCD38ÀLinÀ and CD34+CD38ÀLinÀ cells cultured in the presence or absence of hJagged-1 Progenitor content for each cell subset was measured by enumerating the CFU in methylcellulose cultures following 10 days of serum-free ex vivo culture. The plating conditions are outlined in Materials and methods, and colonies were identified according to standard protocols. CFUmacrophage (CFU-M), CFU-granulocyte (CFU-G), CFU-granulocyte-macrophage (CFU-GM), burst-forming unit-erythroid (BFU-E) and CFUgranulocytic, erythroid, macrophage, megakaryocytic (CFU-GEMM) were identified. The mean percentage of each colony type and the mean number of colonies per 1000 cells plated are shown (n=4-8).
Jagged-1 effects on primitive human CD34À and CD34+ cells FN Karanu et al cultures was significantly higher than in the untreated controls, which was not the case in hJagged-1-treated AC133+CD34À cells (Figure 4bi and ii).
Discordant expression of Notch receptors in progeny CD34+ cells derived from CD34À parents compared to de novo isolated CD34+ cells
CD34Àcells have been considered to represent precursors of CD34+cells because of their ability to acquire the CD34+ phenotype in vitro. 25 Based on our similar observations (Figure 4a) , we investigated whether CD34+ progeny arising from initial CD34Àcells (AC133+CD34À) and CD34+ (CD34+CD38À) cells expressed Notch receptor similar to de novo isolated CD34+(CD34+CD38À) cells. Purified AC133+-CD34Àand CD34+CD38Àcells were cultured for 10 days and CD34+cells arising from CD34À or CD34+ parents were isolated and analyzed by RT-PCR for Notch receptor and Fringe expression. Unlike CD34+progeny from CD34+CD38À cells, CD34+ from AC133+CD34À cells did not express detectable levels of either Notch-3 or Notch-4 receptors, although Notch-1 and Notch-2 transcripts were detectable at equivalent cDNA concentrations ( Figure 5 ). Fringe was expressed in all CD34+ progeny that were investigated ( Figure 5 ). The absence of Notch-3 and Notch-4 from CD34+ daughter cells is similar to their expression profiles from CD34À parents cells from which they were derived, suggesting a tight regulatory control on Notch receptor expression that is independent of differentiation and/or acquisition of CD34+. Since Fringe was not found to be differentially expressed, we suggest that the absence of Notch-3 and Notch-4 expression may best associate with the lack of responsiveness of this population or its CD34+ progeny to Jagged-1.
Discussion
The use of hematopoietic stem cells as therapeutic targets for hematological recovery following radiation and chemotherapy treatment for a wide range of malignant disorders of the blood, including leukemia, is an increasingly attractive and feasible approach for the management of these diseases. 40, 41 However, the advancement of these therapies is greatly limited by the lack of definite phenotypic characterization of stem cells, and the determination of growth factor conditions that facilitate their ex vivo expansion prior to transplantation. 42 While expression of surface CD34 antigen has been traditionally used as the marker for stem cells capable of multilineage repopulation, recent findings that cells devoid of the CD34 antigen (CD34À) are capable of repopulation 22, 24, 25, 27 have provided renewed interest in the CD34À cells as an alternative source of cells that could be used alone or in conjunction with the CD34+ cells for clinical transplantation. Furthermore, since CD34À cells appear to be more long-term engrafting while the CD34+ cells are short-term engrafting, 27 the use of both populations in clinical transplantation procedures could greatly shorten the recovery time and improve long-term engraftment.
The Notch signaling system has been shown to play a role in regulation of hematopoiesis including the delay of differentiation and proliferation of purified cells, indicating its potential as a growth factor for ex vivo expansion of primitive cells prior to clinical transplantation. 15, 43 Our group has previously shown that addition of Notch ligands to cultured CD34+CD38À cells promotes the maintenance and expansion of cells capable of repopulating immune-deficient mice. 13, 19 In this report, we have compared the effect of the Notch ligand Jagged-1 on primitive CD34À and CD34+ cells by analyzing the pattern of Notch gene expression and examining the effect of adding Jagged-1 effects on primitive human CD34À and CD34+ cells FN Karanu et al Jagged-1 to cultured cells in vitro. Similar to their CD34+ and AC133ÀCD34À counterparts, purified AC133+CD34À hematopoietic cells expressed the Notch-1 and Notch-2, as well as the ligand Jagged-1. Surprisingly, AC133+CD34À cells did not express detectable levels of either Notch-3 or Notch-4 receptors, unlike AC133ÀCD34À and CD34+CD38À subsets (Figure 2) . Addition of hJagged-1 did not promote the maintenance or expansion of total cell number, CFU, or primitive LTC-ICs derived from CD34À cells. Collectively, these results indicate that Jagged-1 influences both the proliferative and differentiative capacities of de novo isolated CD34+ cells, without inducing similar responses in their more primitive CD34À precursors.
Between 12 and 15% of cultured CD34À cells acquired the CD34+ phenotype after 10 days in culture. However, Notch-3 and Notch-4 were not expressed upon differentiation into CD34+ progeny, although both Notch-1 and Notch-2 were detectable. Unlike the CD34+ progeny from CD34À parents, CD34+ cells from CD34+ parents continued to express Notch-1 to Notch-4 ( Figure 5 ). Since de novo isolated CD34+ cells and their CD34+ progeny were Notch-3 and Notch-4 positive, these results indicate the first molecular distinction between CD34+ cells developed from primitive CD34À cells, vs CD34+ phenotype isolated from primary human hematopoietic tissue, or their progeny. These differences in Notch-3 and Notch-4 expression between de novo isolated and postculture CD34+ cells further suggested that the two cell subsets are biologically distinct, despite their CD34+ phenotype. Since little is presently known about the binding specificity of Jagged-1 to the different forms of the Notch receptors, it is not clear whether the lack of Notch-3 and Notch-4 expression is responsible for the apparent lack of positive responsiveness of the AC133+ CD34À cells to Jagged-1. One line of evidence to support this as a potential mechanism comes form Uyttendale's group, which using an endothelial cell line has shown that Jagged-1 may act via Notch-4. 44 However, because of the presence of multiple Notch receptors and ligands, and a whole array of modulators that appear to act in context-specific manner, 37, 45 there are other potential expalanation for the lack of reponse of CD34À cells to Jagged-1. For instance, Jagged-1-induced activation through Notch-1 and Notch-2 has been shown to be negatively regulated by the expression of Fringe in the receiving cell. 4, 38 Fringe was expressed in both CD34À and CD34+ cells using both de novo isolated and cultured cells (Figure 2 and 5) , making it unlikely to be solely negatively regulating Jagged-1 in CD34À cells, and not CD34+ cells. Thus, our data confirm that both molecular and functional differences exist in CD34À and CD34+ cells, which may be of significance in any efforts aimed at using and developing both cell types for cellular therapies.
Although Notch signaling plays a role in the regulation and development of hematopoietic cells, this effect is modulated and regulated by other growth factors and cytokines. 16, 46 The growth factor conditions used here have been optimized for CD34+ cells, and may not optimally support CD34À subsets. Data presented here show differences in response to treatment with soluble hJagged-1 between the CD34À and the CD34+ cells, with Jagged-1 treatment failing to enhance overall proliferation or maintenance of clonogenic capacity in the CD34À cells. This lack of defined, optimal growth factor conditions specific to CD34À cells may account, at least in part, for the failure of Jagged-1 treatment to positively regulate CD34À cells. We are currently testing this hypothesis by investigating which growth factor combinations are better able to support CD34À cells in ex vivo culture. The effects of soluble hJagged-1 and other Notch ligands including Delta family tested under optimized culture Expression of Notch receptors and Fringe among CD34+ cells derived from CD34À or CD34+ parents. Expression of Notch receptors and Fringe by postculture CD34+ cells cultured in the presence or absence of hJagged-1 was analyzed by RT-PCR. The PCR products were isolated and were sequenced to verify specificity of the genes amplified (sequence data not shown).
conditions for primitive CD34À cells may provide further insights into the apparent lack of positive response of CD34À cells to Notch signaling.
